Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Christoph Kahlert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4124-7918; OpenAlex author ID A5059644277. Sources: OpenAlex.

Their work

Papers
33 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
126
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 7 papers · 2023: 3 papers · 2024: 1 paper · 2025: 8 papers · 2026: 3 papers

Papers 33

  1. Arp2/3 complex and β1 integrin drive an invasive front through extracellular matrix adaptation in pancreatic cancer. Co-author DOI 10.1002/ijc.70376↗
  2. Oncogenic KRAS Regulates Secretion of Extracellular Vesicles and Surface Membrane Charge via Regulation of Phosphatidylserine in Pancreatic Cancer. Co-author DOI 10.1021/acsnano.6c08263↗
  3. Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. First author DOI 10.1245/s10434-026-19264-2↗
  4. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  5. 17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing? Co-author DOI 10.1016/j.esmogo.2025.100218↗
  6. ChatGPT vs. surgeons on pancreatic cancer queries: accuracy & empathy evaluated by patients and experts. Last author DOI 10.1016/j.hpb.2024.11.012↗
  7. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  8. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  9. Extracellular vesicles from pancreatic cancer and its tumour microenvironment promote increased Schwann cell migration. Last author DOI 10.1038/s41416-024-02915-0↗
  10. The influence of clinical risk factors on the classification of human cancer-associated fibroblasts in PDAC and pancreatitis patients. Last author DOI 10.1038/s44276-025-00150-5↗
  11. Human multiethnic radiogenomics reveals low-abundancy microRNA signature in plasma-derived extracellular vesicles for early diagnosis and molecular subtyping o… Co-author DOI 10.7554/elife.103737↗
  12. Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02488-4↗
  13. Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. Co-author DOI 10.1038/s41698-023-00459-9↗
  14. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patient… Last author DOI 10.1186/s13045-023-01404-w↗
  15. RAB27B expression in pancreatic cancer is predictive of poor survival but good response to chemotherapy. Last author DOI 10.3233/cbm-220460↗
  16. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. Co-author DOI 10.1002/path.5906↗
  17. Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Co-author DOI 10.1038/s41586-022-05062-9↗
  18. Label-free differentiation of human pancreatic cancer, pancreatitis, and normal pancreatic tissue by molecular spectroscopy. First author DOI 10.1117/1.jbo.27.7.075001↗
  19. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. Co-author DOI 10.1172/jci.insight.152761↗
  20. Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers14041074↗
  21. Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer. Co-author DOI 10.3390/cancers14194605↗
  22. Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents. Co-author DOI 10.3390/jpm12030478↗
  23. Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer. Co-author DOI 10.1093/glycob/cwab088↗
  24. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Co-author DOI 10.1038/s41388-020-1186-7↗
  25. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer. First author DOI 10.3390/ijms20133305↗
  26. [Early stage pancreatic cancer]. Co-author DOI 10.1007/s00104-017-0569-y↗
  27. Multiple antibodies identify glypican-1 associated with exosomes from pancreatic cancer cells and serum from patients with pancreatic cancer Co-author DOI 10.1101/145706↗
  28. Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. Last author DOI 10.1186/s12885-017-3225-5↗
  29. Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. Co-author DOI 10.18632/oncotarget.20315↗
  30. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Co-author DOI 10.1038/nature14581↗
  31. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. Co-author DOI 10.1074/jbc.c113.532267↗
  32. Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.2651↗
  33. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. Co-author DOI 10.1186/1471-2407-11-275↗

Closest collaborators

The 25 strongest of 126 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jürgen Weitz · 12 shared papers, 2011–2025 · strength 1.54
  2. Christoph W. Michalski · 4 shared papers, 2025–2026 · strength 0.82
  3. Susanne Roth · 4 shared papers, 2023–2025 · strength 0.70
  4. Ulf D. Kahlert · 4 shared papers, 2022–2025 · strength 0.70
  5. Adrian M. Seifert · 5 shared papers, 2020–2025 · strength 0.70
  6. Lena Seifert · 5 shared papers, 2020–2025 · strength 0.70
  7. Martin Loos · 3 shared papers, 2025–2026 · strength 0.70
  8. Marius Distler · 5 shared papers, 2018–2023 · strength 0.61
  9. Chao Fang · 3 shared papers, 2025–2026 · strength 0.59
  10. Ingrid Herr · 3 shared papers, 2025–2026 · strength 0.59
  11. Mathieu Pecqueux · 5 shared papers, 2014–2025 · strength 0.58
  12. Jorg H. Kleeff · 3 shared papers, 2025 · strength 0.58
  13. Max Heiduk · 4 shared papers, 2020–2025 · strength 0.56
  14. Thilo Welsch · 6 shared papers, 2011–2022 · strength 0.56
  15. Raghu Kalluri · 5 shared papers, 2014–2026 · strength 0.52
  16. Christian P. Pilarsky · 5 shared papers, 2014–2023 · strength 0.48
  17. Thilo Hackert · 2 shared papers, 2023–2026 · strength 0.42
  18. Bo Kong · 2 shared papers, 2025 · strength 0.42
  19. Christoph Reißfelder · 5 shared papers, 2015–2022 · strength 0.39
  20. Zipeng Lu · 2 shared papers, 2025 · strength 0.34
  21. Yifeng Sun · 2 shared papers, 2025 · strength 0.34
  22. Hongzhen Li · 2 shared papers, 2025 · strength 0.34
  23. Zhiheng Zhang · 2 shared papers, 2025 · strength 0.34
  24. Shuang Nie · 2 shared papers, 2025 · strength 0.34
  25. Nuh N. Rahbari · 5 shared papers, 2014–2022 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.